Modulating MSC Secretome Composition Using Stilbene Catalysts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for culturing mesenchymal stem cells (MSCs) face challenges such as high capital investment, costly cell culture, complicated safety and quality management issues, short survival duration, and invasive procedures for cell collection, along with difficulties in controlling the secretome production and composition for therapeutic applications.
Innovation Solution
A method involving the use of stilbene or nicotinamide compounds as catalysts in cell culture media to modulate the secretome production of MSCs, either simultaneously or sequentially, to control the secretome composition and enhance therapeutic applications like tissue regeneration and wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are cultured for therapeutic applications, then therapeutic capacity is improved, but cost and complexity of cell culture increase
Solution Approach 1:
The patent extracts the secretome from living mesenchymal stem cells through culture media collection, creating a cell-free therapeutic product. This eliminates the need for complex living cell culture maintenance while preserving therapeutic benefits, directly resolving the contradiction between therapeutic capacity and culture complexity
Solution Approach 2:
The patent creates a copy of the stem cell secretome in culture media that can be stored and transported without requiring living cells. This copied secretome product maintains therapeutic functionality while eliminating the complexity of maintaining live cell cultures during storage and distribution
2Quantity of substance
If mesenchymal stem cells are cultured for large numbers, then therapeutic quantity is improved, but capital investment and operating costs increase
Solution Approach 1:
The patent performs preliminary action by collecting and concentrating secretome in culture media during the cell culture process, then freezing and storing it for later use. This preliminary collection allows bulk production of secretome that can be stored indefinitely, eliminating the need for continuous expensive cell culture operations while maintaining large quantities for therapeutic use
3Reliability
If mesenchymal stem cells are used for therapy, then regenerative capacity is improved, but survival duration decreases
Solution Approach 1:
The patent extracts the secretome from living cells and delivers it as a cell-free product. This extracted secretome contains all the regenerative signaling molecules without the limitations of cell survival, allowing the therapeutic effect to persist as long as the secretome remains stable in the patient's body, thus resolving the short survival duration issue while maintaining regenerative capacity
4Quantity of substance
If invasive procedures are used for cell collection, then cell quantity is improved, but patient discomfort increases
Solution Approach 1:
The patent creates a copy of the therapeutic secretome that can be produced in large quantities from donor cells, then stored and administered without requiring repeated invasive collections from the patient. This copied secretome product eliminates the need for ongoing invasive procedures while maintaining adequate therapeutic quantity
5Reliability
If secretome production is increased for therapy, then therapeutic efficacy is improved, but control of composition becomes difficult
Solution Approach 1:
The patent applies parameter changes by using specific catalyst compounds (stilbenes and nicotinamides) at controlled concentrations to modulate secretome production. These chemical parameters can be precisely controlled during culture to achieve desired secretome composition and quantity, resolving the contradiction between increasing therapeutic efficacy and maintaining compositional control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for controlled production of MSC secretome, enhancing therapeutic capacity, reducing costs, and improving the efficacy of cell-free therapies by providing a shelf-stable composition for regenerative treatments, while minimizing issues like tumorigenicity and immune compatibility.
Implementation Method 1
combining a cell population with a media that includes a catalyst compound, which can include a stilbene or a nicotinamide compound
Data Source
AI summary
Methods for culturing cells, compositions comprising the cell culture product, and applications for the compositions are described. Methods include culturing cells with a media that includes a catalyst compound, which can include a stilbene or a nicotinamide compound, so as to control the secretome of the cells. Compositions that include the cell culture product include the cell secretome or components thereof in conjunction with at least one catalyst compound. Products can be utilized as a cell culture media or can be utilized in therapeutic applications.